https://www.selleckchem.com/products/Eloxatin.html
The sodium-glucose cotransporter type 2 inhibitors reduce mortality and heart failure (HF) hospitalizations. The underlying mechanisms remain unclear but seem to be irrespective of glucose-lowering properties. This study aims to evaluate the impact of empagliflozin on myocardial biomechanics and correlation with markers of adverse remodeling. Following myocardial infarct induction to create a model of HF, 14 pigs were randomly assigned in a 11 ratio to receive either empagliflozin 10 mg daily or placebo for 2months. Speckle-tracking ec
Like
Comment
Share
